bamlanivimabetesevimab combination two monoclonal antibodies bamlanivimab etesevimab administered together via intravenous infusion treatment types antibody target surface spike protein bamlanivimab etesevimab administered together authorized united states treatment mildtomoderate people aged twelve years age older weighing least kilograms lb positive results direct viral testing high risk progression severe including hospitalization also authorized administered together use exposure virus postexposure prophylaxis pep authorized preexposure prophylaxis prevent exposed january us food drug administration fda revised authorizations two monoclonal antibody treatments bamlanivimabetesevimab administered together casirivimabimdevimab limit use recipients likely infected exposed variant susceptible data show treatments highly unlikely active omicron variant circulating high frequency throughout united states treatments authorized use us states territories jurisdictions etesevimab monoclonal antibody surface spike protein eli lilly licensed etesevimab junshi bamlanivimab monoclonal antibody mab directed spike protein aim block viral attachment entry human cells thus neutralizing virus help preventing treating data supporting emergency use authorization eua bamlanivimab etesevimab based randomized doubleblind placebocontrolled clinical trial nonhospitalized participants mild moderate symptoms high risk progressing severe participants received single infusion bamlanivimab milligrams etesevimab milligrams together received primary endpoint related hospitalizations death cause days hospitalization death occurred participants received placebo compared participants treated bamlanivimab milligrams etesevimab milligrams administered together ten deaths occurred placebo thus allcause death significantly lower bamlanivimab etesevimab group placebo february united states government agreed purchase doses drug million per february fda issued emergency use authorization eua bamlanivimab etesevimab administered together treatment mild moderate people twelve years age older weighing least kilograms lb test positive high risk progressing severe authorized use includes treatment years age older certain chronic medical conditions bamlanivimab etesevimab administered together resulted lower risk resistant viruses developing treatment compared bamlanivimab administered alone treatments available eua expected benefit people high risk disease april fda revoked emergency use authorization eua allowed investigational monoclonal antibody therapy bamlanivimab administered alone used treatment mildtomoderate adults certain pediatric eua issued eli lilly february committee medicinal products human use chmp european medicines agency ema started rolling reviews data use monoclonal antibodies casirivimabimdevimab bamlanivimabetesevimab bamlanivimab treatment march chmp concluded bamlanivimab etesevimab used together treat confirmed people require supplemental oxygen high risk disease becoming chmp also looked use bamlanivimab alone concluded despite uncertainties around benefits monotherapy considered treatment october chmp ended rolling review article incorporates public domain material united states department health human services httpsenwikipediaorgwikibamlanivimabetesevimab